The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway. EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in January 2021, performed a systematic literature review according to EULAR's standard operating procedures and completed a set of updated overarching principles and recommendations in July 2021. Two points to consider were added in November 2021, because of recent developments pertaining to additional vaccination doses.

EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update / R.B.M. Landewé, F.P.B. Kroon, A. Alunno, A. Najm, J.W. Bijlsma, G.R. Burmester, R. Caporali, B. Combe, R. Conway, J.R. Curtis, O. Elkayam, L. Gossec, M.W. Heijstek, L. Haupt, A. Iagnocco, J.D. Isaacs, I.Á. Juhász, S. Makri, X. Mariette, I.B. Mcinnes, P. Mehta, U. Mueller-Ladner, H. Schulze-Koops, J.S. Smolen, D. Wiek, K.L. Winthrop, V. Navarro-Compán, P.M. Machado. - In: ANNALS OF THE RHEUMATIC DISEASES. - ISSN 0003-4967. - 81:12(2022 Dec), pp. 1628-1639. [10.1136/annrheumdis-2021-222006]

EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update

R. Caporali;
2022

Abstract

The first EULAR provisional recommendations on the management of rheumatic and musculoskeletal diseases (RMDs) in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), largely based on expert opinion, were published in June 2020. Since then, an unprecedented number of clinical studies have accrued in the literature. Several SARS-CoV-2 vaccines have been approved for population-wide vaccination programmes in EULAR-affiliated countries. Studies regarding vaccination of patients with (inflammatory) RMDs have released their first results or are underway. EULAR found it opportune to carefully review to what extent the initially consensus expert recommendations stood the test of time, by challenging them with the recently accumulated body of scientific evidence, and by incorporating evidence-based advice on SARS-CoV-2 vaccination. EULAR started a formal (first) update in January 2021, performed a systematic literature review according to EULAR's standard operating procedures and completed a set of updated overarching principles and recommendations in July 2021. Two points to consider were added in November 2021, because of recent developments pertaining to additional vaccination doses.
Covid-19; antirheumatic agents; vaccination
Settore MED/16 - Reumatologia
dic-2022
23-feb-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
1628.full.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 793.81 kB
Formato Adobe PDF
793.81 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/943110
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 106
  • ???jsp.display-item.citation.isi??? 96
social impact